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Abstract
 
In autoimmune hemolytic anemia (AIHA), circulating red blood cells (RBCs) opsonized
 
with autoantibody are recognized by macrophage Fc
 
g
 
 and complement receptors. This trig-
gers phagocytosis and elimination of RBCs from the circulation by splenic macrophages. We
recently found that CD47 on unopsonized RBCs binds macrophage signal regulatory protein
 
a
 
 (SIRP
 
a
 
), generating a negative signal that prevents phagocytosis of the unopsonized
RBCs. We show here that clearance and phagocytosis of opsonized RBCs is also regulated
by CD47-SIRP
 
a
 
. The inhibition generated by CD47-SIRP
 
a
 
 interaction is strongly attenu-
ated but not absent in mice with only residual activity of the phosphatase Src homology 2 do-
main–containing protein tyrosine phosphatase (SHP)-1, suggesting that most SIRP
 
a
 
 signal-
ing in this system is mediated by SHP-1 phosphatase activity. The macrophage phagocytic
response is controlled by an integration of the inhibitory SIRP
 
a
 
 signal with prophagocytic
signals such as from Fc
 
g
 
 and complement receptor activation. Thus, augmentation of inhibi-
tory CD47-SIRP
 
a
 
 signaling may prevent or attenuate RBC clearance in AIHA.
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Introduction
 
In autoimmune hemolytic anemia (AIHA),
 
1 
 
“self” RBCs
are opsonized with autoantibody and complement, and
 
RBC phagocytosis is mediated primarily by Fc
 
g
 
 receptors,
with some amplification from complement receptors (1–4).
We recently found that unopsonized RBCs from CD47-
deficient mice are recognized and rapidly phagocytosed by
splenic red pulp macrophages in wild-type recipients.
CD47 on normal RBCs binds to and activates signal regu-
latory protein 
 
a
 
 (SIRP
 
a
 
) on the macrophage, which inhib-
its macrophage activation and phagocytosis (5). Thus, red
pulp macrophages have phagocytic receptors capable of
recognizing normal “self” RBCs, and the CD47-SIRP
 
a
 
signal is sufficient to counteract this signal (5). It is unclear
how this capacity of CD47 (also known as integrin-associ-
ated protein [IAP]) is related to its function as a signaling
molecule mediating the stimulatory effect of Arg-Gly-Asp
(RGD)-containing matrix proteins on phagocytosis (6, 7).
 
Upon ligation and cross-linking, SIRP
 
a
 
 is tyrosine phos-
phorylated by Src family kinases at its intracellular immu-
noreceptor tyrosine-based inhibitory motifs (ITIMs [8]).
These phosphorylated motifs bind the tyrosine phosphatases
Src homology 2 domain–containing protein tyrosine phos-
phatase (SHP)-1 and SHP-2, thereby recruiting them to the
cell surface and activating them. In macrophages, SHP-1 is
the predominant ligand, but SHP-2 is also present (8). These
phosphatases then interrupt signaling from tyrosine kinase–
dependent receptors, e.g., the M-CSF receptor c-fms, likely
by direct receptor dephosphorylation (9). Several other sig-
naling molecules such as Grb2, son of sevenless (SOS), and
the Src kinase Fgr also bind the phosphorylated SIRP
 
a
 
ITIM (9, 10). SIRP
 
a
 
 when coligated with Fc
 
e
 
 receptors
prevents or attenuates Fc
 
e
 
 receptor signaling (11). Also, the
Src family kinase Fgr was found to be associated with SIRP
 
a
 
upon Fc
 
g
 
 receptor cross-linking in murine macrophages, re-
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, signal regulatory protein 
 
a
 
. 
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Target CD47 Inhibits Phagocytosis
 
sulting in recruitment of SHP-1 to SIRP
 
a
 
 and decrease in
phagocytosis (10). However, the in vivo effect of SIRP
 
a
 
signaling in the context of Fc receptors is not known.
Although CD47
 
2
 
/
 
2
 
 RBCs are recognized and elimi-
nated by splenic red pulp macrophages in vivo (5), the re-
ceptor mediating this positive recognition has not been
identified. We will refer to this functional activity as the
“RBC receptor.” Due to the inhibitory signal generated by
ligation of macrophage SIRP
 
a
 
 by target CD47, wild-type
RBCs are not eliminated (5). This leaves two important
questions, relevant to AIHA, that were investigated in this
study: first, does the CD47-SIRP
 
a
 
 signal regulate only this
“RBC receptor,” or does it also affect the outcome of liga-
tion of other phagocytic receptors? Second, is the outcome
determined by the relative strength of the prophagocytic
and inhibitory signals, or is the inhibitory signal dominant?
We address these questions by determining the in vivo
clearance and in vitro phagocytosis of wild-type and
CD47
 
2
 
/
 
2
 
 RBCs opsonized with IgG or complement. The
strength of the activating signal was regulated by control-
ling the level of opsonization, and SIRP
 
a
 
 signaling was
manipulated by regulating the amount of CD47 available
on the target cell and by using mice and macrophages defi-
cient in SHP-1 activity, a downstream mediator of SIRP
 
a
 
signaling in macrophages (8).
 
Materials and Methods
 
Reagents.
 
Rat anti-murine CD47 (mIAP301; IgG2a; refer-
ence 7) was purified from tissue culture supernatant by ammo-
nium sulfate precipitation and ion-exchange chromatography
using DEAE sephacel (Amersham Pharmacia Biotech). Fab
fragments of mIAP301 were prepared by papain digestion and
purification using DEAE ion-exchange chromatography. Rat
anti-murine SIRP
 
a
 
 (P84; IgG1; reference 12) was purified from
tissue culture supernatant by ammonium sulfate precipitation and
protein-G chromatography using the mAb Trap II kit (Amer-
sham Pharmacia Biotech). Human serum albumin (HSA) was
from Alpha, Therapeutic Corp. Rabbit anti-murine RBC antise-
rum was from Cappel, and the rabbit anti-murine RBC IgG frac-
tion was purified by protein-G chromatography (Amersham
Pharmacia Biotech). Rat anti-murine CD14 (IgG1), rat anti-
murine CD24 (IgM), and biotinylated anti-CD24 were from BD
PharMingen. Avidin-FITC was from Molecular Probes. FITC-
labeled goat anti–rabbit IgG and PKH26 were from Sigma-
Aldrich. Chemicals were of the highest grade available and pur-
chased from Sigma-Aldrich unless otherwise specified
 
.
Mice.
 
Male and female CD47
 
2
 
/
 
2
 
 C57BL/6J mice, back-
crossed to C57BL/6J (The Jackson Laboratory) for 16 or more
generations, and their heterozygous and homozygous littermates
were from our own breeding colony (7). Motheaten viable mice
(me
 
v
 
/me
 
v
 
) were obtained from The Jackson Laboratory, and Fc
 
g
 
receptor
 
2
 
/
 
2
 
 mice were obtained from Taconics. CD18
 
2
 
/
 
2
 
 mice
were a gift from Drs. D. Bullard (University of Alabama, Bir-
mingham, AL) and A.L. Beaudet (Baylor College of Medicine,
Houston, TX) (13). Animals were kept in accordance with Na-
tional Institutes of Health and local guidelines and maintained in a
specific pathogen-free barrier facility.
 
Opsonization of Murine RBCs.
 
IgG-opsonized murine RBCs
(RBC-IgG) were obtained by incubating washed RBCs with a
 
1:2 or 1:10 dilution (in vivo experiments; high and low opsoniza-
tion, respectively) or a 1:5 dilution (in vitro experiments) of rab-
bit IgG anti-murine RBC (1 mg/ml) for 20 min at 37
 
8
 
C. For
complement-opsonized murine RBCs (RBC-C3bi; reference
14), washed murine RBCs were first incubated with subaggluti-
nating dilution of mAb rat IgM anti-CD24 (HSA) for 30 min at
37
 
8
 
C. Then, RBC-IgM were incubated in 5% C5-deficient
mouse serum (The Jackson Laboratory) for 60 min at 37
 
8
 
C. For
in vitro phagocytosis assays, opsonized RBCs were finally washed
and resuspended in HBSS with 1% HSA at 5 
 
3
 
 10
 
8
 
/ml. Op-
sonized RBCs for in vivo experiments were prepared as de-
scribed below. Equivalence of opsonization levels on CD47
 
1
 
/
 
1
 
and CD47
 
2
 
/
 
2
 
 RBCs was verified by flow cytometry, using
FITC-labeled goat anti–rabbit IgG for IgG-opsonized RBCs or
biotinylated anti-CD24 and avidin-FITC for complement-
opsonized RBCs.
 
In Vivo Clearance of Unopsonized or Opsonized RBCs.
 
Washed
wild-type or CD47
 
2
 
/
 
2
 
 RBCs were stained with the fluorescent
dye PKH26 (Sigma-Aldrich) according to the manufacturer’s
protocol and then washed three times in sterile PBS with 0.1%
HSA. In experiments where IgG-opsonized RBCs (RBC-IgG)
were used, PKH26-labeled RBCs were opsonized with rabbit
IgG anti-murine RBCs as described above, and washed three
times in sterile PBS. RBCs or RBC-IgG were finally resus-
pended in sterile pyrogen-free 0.9% NaCl to 30% (vol/vol). Re-
cipient mice were given 200 
 
m
 
l of the stained RBCs or RBC-
IgG and the clearance of fluorescent RBCs was followed using
flow cytometry (Epics XL; Coulter Corp.) of 5-
 
m
 
l blood samples
collected from a tail vein at the time points indicated. The frac-
tion of fluorescent RBCs, of total number of recipient RBCs
studied (100,000/sample), was determined. The data were nor-
malized to the fraction at 30 min after injection (5). Use of the
5-min time point as a reference gave similar results, although the
experimental variation was higher this early after injection (not
shown).
 
Preparation of Bone Marrow Macrophages.
 
Bone marrow was
collected from femurs and tibias of donor mice, and bone mar-
row macrophages prepared as described previously (15).
 
RBC Phagocytosis in Bone Marrow Macrophages In Vitro.
 
Phago-
cytosis was assessed using bone marrow macrophages in suspen-
sion (10). Washed macrophages (2 
 
3
 
 10
 
5
 
) were centrifuged with
7.5 
 
m
 
l of RBC-IgG or 25 
 
m
 
l of RBC-C3bi for 1 min at 100 
 
g
 
and then gently resuspended in 100 
 
m
 
l of buffer. For phagocy-
tosis of RBC-C3bi, 30 ng/ml of Phorbol dibutyrate (PDBu) and
1 mM MnCl
 
2
 
 were added to stimulate ingestion (10). Where in-
dicated, anti-CD47 (mAb mIAP301), anti-SIRP
 
a
 
 (mAb P84), or
control Ab (anti-CD14) were also added at 10 
 
m
 
g/2 
 
3
 
 10
 
5
 
 mac-
rophages. After incubation for 30 min at 37
 
8
 
C, uningested RBCs
were removed by hypotonic lysis. Phagocytosis was assessed by
phase contrast microscopy and quantitated as a phagocytic index
(the number of RBCs ingested/100 macrophages).
 
Results
 
CD47 Increases Survival of IgG-opsonized RBCs In Vivo.
 
Unopsonized CD47
 
2
 
/
 
2
 
 RBCs are recognized and elimi-
nated by splenic red pulp macrophages in wild-type mice,
which suggests that these macrophages have activating
“RBC receptors” (5). This activating signal is under nor-
mal circumstances counteracted by an inhibitory signal re-
sulting from CD47-SIRP
 
a
 
 interaction (5). To determine if
the CD47-SIRP
 
a
 
 signal is also integrated with signals from 
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other macrophage activating receptors, we investigated
how CD47-SIRP
 
a
 
 interaction affects macrophage Fc
 
g
 
 and
complement receptor–mediated elimination of opsonized
RBCs.
To investigate the interaction of CD47-SIRP
 
a
 
 signaling
with signals from macrophage Fc
 
g
 
 receptors in vivo, we
opsonized CD47
 
2
 
/
 
2
 
 and wild-type (CD47
 
1
 
/
 
1
 
) RBCs to
identical levels with rabbit anti–mouse RBC IgG. Op-
sonized RBCs were produced at both high and low levels
of opsonization, with IgG on highly opsonized RBCs
present at approximately five times the level detected on
the low opsonized cells (by flow cytometry; not shown). At
each level, opsonization of CD47
 
2
 
/
 
2
 
 and wild-type RBCs
was identical (assessed by flow cytometry; see Materials and
Methods). Unopsonized CD47
 
2
 
/
 
2
 
 RBCs are rapidly elimi-
nated in wild-type recipients, whereas wild-type RBCs are
not (5; Fig. 1). Increasing levels of opsonization accelerated
the clearance of both CD47
 
2
 
/
 
2
 
 and wild-type RBCs (Fig.
1). Thus, the rate of elimination was determined by both
target cell CD47 and by the level of opsonization.
Virtually identical results were obtained in CD18
 
2
 
/
 
2
 
mice (13), suggesting that the increased rate of clearance
obtained by IgG opsonization is mediated by macrophage
Fc
 
g
 
 receptors, rather than by secondary effects from com-
plement and complement receptors (not shown).
 
Phagocytosis of IgG-opsonized RBCs by Bone Marrow–
derived Macrophages Is Regulated by CD47-SIRP
 
a
 
.
 
Next, we
turned to an in vitro system to more closely characterize
the integration of Fc
 
g
 
 receptor and SIRP
 
a
 
 signals in mac-
rophages. Splenic red pulp macrophages phagocytose un-
opsonized RBCs, making it hard to isolate the effect of
opsonization (5). Thus, we used bone marrow–derived
macrophages (BMMs), which do not recognize unop-
sonized RBCs (5). Wild-type RBCs were opsonized with
rabbit anti–mouse RBC IgG to a level resulting in moder-
ate phagocytosis (93 
 
6
 
 16 RBCs per 100 macrophages;
Fig. 2 A). Identically opsonized CD47
 
2/2 RBCs yielded
markedly higher levels of phagocytosis (398 6 57 RBCs
per 100 macrophages; Fig. 2 A). Anti-SIRPa mAb P84 in-
creased phagocytosis of wild-type, but not of CD472/2
Figure 1. Clearance of IgG-opson-
ized RBCs in vivo is regulated by
CD47 on the RBCs. Wild-type recipi-
ent mice were intravenously injected
with PKH26-labeled wild-type RBCs
(A; filled symbols) or CD472/2 RBCs
(B; open symbols). RBCs were op-
sonized to different levels with rabbit
polyclonal anti–mouse RBCs IgG to
obtain low or highly opsonized (ops.)
RBCs. Flow cytometric analysis of op-
sonized RBCs showed identical op-
sonization of wild-type and CD472/2
RBCs, and a fivefold difference in the
level of opsonization between low- (cir-
cles) and high-opsonized (squares)
RBCs. After extensive washing, 200 ml of low- or high-opsonized RBCs or unopsonized (Unops.) RBCs (triangles; 30% vol/vol in pyrogen-free 0.9%
NaCl) was intravenously injected into wild-type recipient mice. Clearance of labeled RBCs was followed using flow cytometry of 5-ml blood samples
collected from a tail vein at the time points indicated. Data are mean 6 SD for three mice in each group. The rate of clearance increases with increased
degree of opsonization and is at each level higher for CD472/2 targets than for CD471/1 RBCs.
Figure 2. Target cell CD47 inhibits Fcg receptor–mediated phagocyto-
sis of opsonized RBCs in BMMs via ligation of macrophage SIRPa. (A)
Effects of anti-SIRPa mAb P84 on phagocytosis of IgG-opsonized RBCs
in CD47 wild-type (Wt) BMMs was assayed in medium alone (white
bars), in the presence of 10 mg anti-SIRPa mAb P84 (black bars), or in
the presence of control mAb anti-CD14 (hatched bars). Wild-type RBCs
are phagocytosed at a lower rate than CD472/2 RBCs, which can be vir-
tually completely corrected by anti-SIRPa mAb P84. The rate of
CD472/2 RBC phagocytosis can be significantly enhanced by increased
opsonization (not shown). Thus, the lack of anti-SIRPa effect on
CD472/2 RBC phagocytosis is not due to saturation of the system. (B)
Effects of anti-CD47 mAb mIAP301 on phagocytosis of IgG-opsonized
wild-type RBCs in wild-type BMMs. Macrophages (Mf) and RBCs
were incubated in medium alone (white bar) or in the presence of 10 mg
Fab fragments of anti-CD47 mAb mIAP301 (black bar). To further sepa-
rate the anti-CD47 blocking effect on macrophage CD47 from that on
RBC CD47, respectively, macrophages only (cross-hatched bar) or RBCs
only (hatched bar) were preincubated with 10-mg Fab fragments of anti-
CD47 mAb mIAP301, extensively washed, and then mixed for assay of
phagocytosis. CD472/2 or wild-type RBCs were opsonized to identical
levels with rabbit anti–mouse RBC IgG and then added to macrophages
(2 3 105) in suspension (100 ml). After 30 min at 378C, uningested RBCs
were lysed and phagocytosis was determined by light microscopy. Results
are expressed as number of RBCs ingested per 100 macrophages (phago-
cytosis index) and are mean 6 SEM for three separate experiments. Liga-
tion of target cell CD47 enhances the phagocytosis of wild-type RBCs to
the level seen with CD472/2 RBCs.858 Target CD47 Inhibits Phagocytosis
RBCs, whereas an isotype-matched control mAb (anti-
CD14) was without effect (Fig. 2 A). The level of CD472/2
RBC phagocytosis could be increased significantly by in-
creased opsonization (beyond 800 RBCs per 100 macro-
phages), showing that the lack of anti-SIRPa effect was not
due to an overall saturation of the system. The level of
phagocytosis of wild-type RBCs in the presence of anti-
SIRPa was not significantly different from that obtained
with CD472/2 RBCs. Thus, phagocytosis of wild-type and
CD472/2 RBCs becomes equivalent when CD47-SIRPa
interaction is prevented by blocking macrophage SIRPa.
This implies that blockade of target cell CD47 would also
enhance phagocytosis of wild-type RBCs to the level seen
with CD472/2 targets.
To test this hypothesis, we added saturating amounts of
anti-CD47 mAb mIAP301 Fab fragments, which block
CD47-SIRPa interaction in vitro (not shown). As ex-
pected, phagocytosis of wild-type RBCs was enhanced
(Fig. 2 B). mAb mIAP301 Fab acted by blocking of CD47
on the target, whereas blocking of macrophage CD47 was
without effect (Fig. 2 B). Thus, SIRPa signals resulting
from interaction with target cell CD47 can attenuate the
phagocytic signal from macrophage Fcg receptors.
Phagocytosis of Complement-opsonized RBCs Is Also Con-
trolled by CD47-SIRPa. Complement receptors are a sec-
ond class of macrophage phagocytic receptors (16). To
study the role of CD47 in complement receptor–mediated
phagocytosis, we opsonized CD472/2 and wild-type
RBCs with C3bi (see Materials and Methods), then incu-
bated them with wild-type BMMs. As shown in Fig. 3,
C3bi-opsonized CD472/2 RBCs were phagocytosed at a
significantly higher rate than wild-type RBCs. Phagocyto-
sis of wild-type RBCs could be augmented to the level of
CD472/2 RBC phagocytosis by the addition of SIRPa-
blocking mAb P84. The level of phagocytosis was the same
in Fcg receptor–deficient macrophages (Fig. 3), showing
that this system is independent of Fcg receptors. Thus, the
phagocytic signals from Fcg receptors, complement recep-
tors, and the RBC receptor are integrated with the inhibi-
tory signal from SIRPa. None of the signals is dominant.
Rather, the outcome is determined by the relative signal
strengths from prophagocytic and inhibitory receptors.
The Tyrosine Phosphatase SHP-1 Is the Main Mediator of
SIRPa Signaling. SHP-1 phosphatase activity is z80% re-
duced in motheaten viable (mev/mev) compared with wild-
type mice (17–19). SIPRa has been shown to be the major
substrate of SHP-1 (8), and SHP-1 is the major phosphatase
associated with SIRPa in macrophages, although SHP-2
predominates in other cells (9, 20, 21). If CD47-SIRPa sig-
naling in macrophages is mediated by SHP-1, mev/mev
mice should lack or show strong reduction of the inhibitory
signal mediated by CD47 on target RBCs. Thus, mev/mev
mice should eliminate opsonized wild-type RBCs at accel-
erated rates similar to those seen with CD472/2 targets.
To test the role of SHP-1 in CD47-SIRPa signaling, we
examined the clearance of low-opsonized (see for example
Fig. 1) wild-type and CD472/2 RBCs in mev/mev mice.
Consistent with our hypothesis, clearance of opsonized
wild-type RBCs in these recipients was independent of
CD47 and accelerated to the rate seen with CD472/2 tar-
gets (Fig. 4). Again, we wished to verify our results in vitro.
As shown in Fig. 5, IgG-opsonized RBCs were phagocy-
tosed by mev/mev BMMs without regard to the presence
or absence of CD47 on the target cells, and at the same rate
as wild-type BMM phagocytosed CD472/2 RBCs. Fur-
Figure 3. Phagocytosis of C3bi-opsonized RBCs is regulated by target
cell CD47 via macrophage SIRPa. BMM (2 3 105) and C3bi-opsonized
wild-type (Wt) or CD472/2 RBCs, in the presence of anti-SIRPa mAb
P84 (10 mg) or control anti-CD14 mAb (10 mg), were incubated with 30
ng/ml of PDBu and 1 mM MnCl2 in a 100-ml volume for 30 min at
378C. Uningested RBCs were lysed and phagocytosis was determined by
light microscopy. Phagocytosis index is number of RBCs ingested per
100 macrophages and is expressed as mean 6 SEM for three separate ex-
periments. To exclude any role of Fcg receptors, the same experiments
were also performed in Fcg receptor–deficient BMMs.
Figure 4. Fcg receptor–mediated clearance of IgG-opsonized RBCs
is independent of target cell CD47 in SHP-1–deficient motheaten via-
ble (mev/mev) mice. (A) mev/mev or (B) wild-type (Wt) mice were in-
travenously injected with PKH26-labeled IgG-opsonized wild-type (d)
or CD472/2 (n) RBCs. Opsonization of RBCs and clearance of in-
jected RBCs was performed and followed as described in the legend to
Fig. 1. Data are mean 6 SD for three mice in each group.859 Oldenborg et al.
thermore, anti-SIRPa mAb P84 had no effect on phagocy-
tosis by mev/mev macrophages. These results are consistent
with the in vivo results shown in Fig. 4. Together, the data
presented suggest that the SIRPa signal in mev/mev mac-
rophages is absent or highly attenuated.
If SIRPa signals exclusively via the SHP-1 phosphatase,
SIRPa is the only receptor for CD47, and CD47 is
the only difference between wild-type (CD471/1) and
CD472/2 RBCs, mev/mev mice should show reduced abil-
ity to distinguish between wild-type and CD472/2 RBCs
also in the absence of opsonization. Surprisingly, the clear-
ance of the two RBC types is as different in mev/mev as in
wild-type mice (Fig. 6). Likely, the residual phosphatase
activity of SHP-1 in mev/mev mouse macrophages is suffi-
cient to allow some signaling from CD47-SIRPa interac-
tion. This signal would be strong enough to counteract the
phagocytic signal from the RBC receptor. Alternatively,
CD47-SIRPa signaling may to a small extent be mediated
independent of SHP-1 phosphatase activity, e.g., via SHP-2.
Additional CD47-SIRPa-independent pathways are very
unlikely, as both anti-SIPRa and anti-CD47 can block the
entire difference between the two RBC types (5; Figs. 2
and 3).
Heterozygote (CD471/2) and wild-type (CD471/1)
RBCs behaved identically in all experiments performed in
wild-type and heterozygote recipients (5; Fig. 6). This sug-
gests that the signal from CD47-SIRPa is significantly
stronger than that from the RBC receptor so that even half
the normal CD47 density suffices to completely suppress
clearance. Interestingly, CD471/2 RBCs in mev/mev mice
are cleared rapidly, albeit slower than CD472/2 RBCs (Fig.
6). This further suggests that the inhibitory signal obtained
from CD47-SIRPa interaction in mev/mev mice is much
weaker than it is in wild-type mice. When RBCs are suffi-
ciently opsonized to also obtain some phagocytosis of wild-
type RBCs, the SIRPa signal in the mev/mev background
must be relatively insignificant compared with the Fcg re-
ceptor signal, as no difference was observed between IgG-
opsonized wild-type and CD472/2 target cells in mev/mev
mice (Fig. 4).
Discussion
Activation of phagocytosis in macrophages is mediated
by several different receptors, including IgG Fcg receptors
and complement receptors (22). Fcg and complement re-
ceptors also play a major role in cell clearance in autoim-
mune processes, such as AIHA. We have recently shown
that CD47, a ubiquitously expressed membrane glycopro-
Figure 5. Phagocytosis of IgG-opsonized RBCs is independent of
CD47 in BMMs from SHP-1–deficient mev/mev mice. BMMs (Mf)
from mev/mev or wild-type (Wt) mice were incubated with IgG-opson-
ized RBCs in medium alone (white bars), in the presence of 10 mg anti-
SIRPa mAb P84 (black bars) or control anti-CD14 mAb (hatched bars).
Phagocytosis was determined as described in the legend to Fig. 2. Data are
presented as mean 6 SEM for three separate experiments.
Figure 6. Residual and attenuated inhibitory CD47-SIRPa signal in
mev/mev mice. Clearance of unopsonized PKH26-labeled CD471/1 (d),
CD471/2 (j), or CD472/2 (n) RBCs in (A) mev/mev or (B) wild-type
(Wt) mice. Clearance of unopsonized RBCs was performed as described
in the legend to Fig. 1. Data are mean 6 SD for three to five mice in
each group.
Figure 7. A model for the regulation of macrophage phagocytosis
based on a summation of positive prophagocytic and negative CD47-
SIRPa–generated signals. Neither type of signal is dominant. Rather, the
decision to phagocytose is based on the summation of weak positive sig-
nals (the RBC receptor), strong positive signals (Fc and complement re-
ceptors), and negative signals (SIRPa). The majority of SIRPa signaling
is mediated via SHP-1 as shown by the marked reduction of the signal in
mev/mev mice. The data presented do not rule out the possibility that a
small subset of the SIRPa signal may be mediated by SHP-2.860 Target CD47 Inhibits Phagocytosis
tein, functions as a marker of “self” on RBCs, and that un-
opsonized murine CD472/2 RBCs are rapidly recognized
and cleared by splenic red pulp macrophages in wild-type
recipients (5). Under normal circumstances, CD47 on
RBCs prevents their elimination by ligating the inhibitory
macrophage receptor SIRPa (5). The data also suggested
that splenic, but not BMMs, have “RBC receptors” capa-
ble of recognizing circulating RBCs (5).
Both CD472/2 and wild-type RBCs are more rapidly
cleared in vivo and more rapidly phagocytosed in vitro as
the level of IgG opsonization is increased (Figs. 1 and 2). At
all levels, CD472/2 RBC are cleared more rapidly than
wild-type cells. This demonstrates that the inhibitory
CD47-SIRPa signal is integrated with the Fcg receptor
signal proximal to the decision to phagocytose, and that
neither the SIRPa nor the Fcg receptor signal is dominant.
Rather the outcome is determined by the relative strength
of the two signals. RBCs opsonized with the complement
fragment C3bi are bound and phagocytosed via the CR3/
aMb2/Mac-1 integrin (16). We also show that comple-
ment-mediated phagocytosis is regulated by the CD47-
SIRPa signal and that again neither signal is dominant (Fig.
3). It is well known that CR3 and Fcg receptors act syner-
gistically (23–26). In vivo, RBCs that are opsonized with
very low levels of IgG are not cleared in the absence of
complement (27). Low levels of complement deposition
alone also fail to trigger phagocytosis, whereas combination
of the two results in rapid clearance in vivo and phagocyto-
sis in vitro (25–27). Thus, phagocytosis is based on the
summation of positive signals from at least Fcg receptors,
complement receptors, and the so far uncharacterized
“RBC receptors,” with the negative signal from SIRPa.
SHP-1 phosphatase activity in mev/mev mice is only
z20% of normal, whereas SHP-2 activity is unaffected by
the mutation (18, 19). The altered RBC clearance in mev/
mev mice suggested strongly attenuated SIRPa signaling ar-
guing that the majority of the CD47-SIRPa signal is de-
pendent on SHP-1 phosphatase activity. This is consistent
with biochemical data for SIRPa-SHP-1 colocalization, the
relative abundance of SHP-1 over SHP-2 in macrophages,
and signaling data both in macrophages and in model sys-
tems (8, 11, 28). Although the data suggest that SHP-1 is
responsible for the majority of CD47-SIRPa signaling, they
do not rule out an accessory role for SHP-2. The signal re-
sulting from CD47-SIRPa interaction in mev/mev mice is
insignificant compared with the activating signal from the
Fcg receptor even with lightly opsonized RBCs (Fig. 4). In
contrast, even this attenuated signal suffices to counteract
the “RBC receptor” on red pulp macrophages, as in mev/
mev mice wild-type levels of CD47 protect from clearance
(Fig. 6). The protection is tenuous, as demonstrated by the
fact that a reduction of CD47 on RBCs by as little as 50%
leads to their rapid elimination in mev/mev mice. In wild-
type mice with normal SIRPa signaling, much higher re-
duction in CD47 levels are required before target RBCs are
significantly cleared (Fig. 6, and unpublished data).
Fig. 7 is a schematic depiction of the semiquantitative
implications of our data. The SIRPa signal generated by
CD47 on normal RBCs is significant and normally coun-
teracts the weak prophagocytic RBC receptor signal. A sig-
nificant signal from Fcg and/or complement receptors is
required to overcome the normal SIRPa signal. This in-
hibitory signal is absent when the target particles are CD47
deficient or attenuated when downstream signaling is re-
duced such as in mev/mev mice.
Self versus nonself discrimination is a cornerstone in host
defense. CD47-SIRPa interaction provides such discrimi-
nation by enhancing the contrast between self and nonself.
A self (CD471) particle can escape phagocytosis even when
it is opsonized to a degree that for a nonself (CD472) parti-
cle would lead to rapid phagocytosis. In type II inflamma-
tory diseases involving cytotoxic self-reactive Abs, Fcg
receptor–mediated mechanisms are known to be of funda-
mental importance (1). Our data shows that CD47-SIRPa
interacts with at least Fcg and complement receptor signals
and that modulation of CD47-SIRPa signaling has drastic
effects on the outcome at all but extreme levels of op-
sonization. This should make CD47-SIRPa appealing as a
means to modulate autoimmune destruction in AIHA and
immune thrombocytopenia (ITP), where sensitized blood
cells are cleared by splenic macrophages.
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